medical care s with Fosamax (Alendronate) and Actonel">New Study Comparing Weekly Osteoporosis Pharmacomedical care s with Fosamax (Alendronate) and Actonel
Fosamax (Alendronate) Maintained or Increased BMD at Hip and Spine for Significantly More Patients than Actonel, with Similar Tolerability, in this 12 Month Study
FOSAMAX Once Weekly (Alendronate sodium) increased bone mineral density (BMD) more than Actonel Once-a-Week (risedronate) with similar tolerability, according to results of the FOSAMAX Actonel Comparison Trial (FACT). This is the first U.S. head-to-head meditate comparing Food and Drug Administration approved once weekly osteoporosis a cures in postmenopausal women with osteoporosis. In this meditate , FOSAMAX provided greater increases in BMD at all sites measured as early as six months, and lowered levels of biochemical markers of bone turnover further within the normal pre-menopausal range than Actonel within three months. Reducing and stabilizing bone turnover, which leads to increased bone density, are important factors in improving bone strength in patients with osteoporosis.
The results of FACT, which was a 12 month meditate , were announced today online in the Journal of Bone and Mineral Research and will be presented on Friday at the American Society for Bone Mineral Research (ASBMR) meeting in Seattle, Wash. A 12-month extension of this double-blind meditate , and a second similarly designed meditate , are currently underway.
FOSAMAX is the only medicine approved by the U.S. Food and Drug Administration for the a cure of osteoporosis to reduce the risk of both spine and hip fractures in postmenopausal women. FOSAMAX is the most prescribed medicine for the a cure of osteoporosis.
“In this 12-month meditate , FOSAMAX demonstrated greater increases in BMD and reductions in bone turnover and similar tolerability compared to Actonel,” said Marc Hochberg, MD, professor of medicine and epidemiology and Preventive Medicine at the University of Maryland-School of Medicine in Baltimore. “Studies like FACT, that make direct “head-to-head” comparisons between a cures, are important because they provide important information to clinicians for use in making a cure decisions for postmenopausal women with osteoporosis.”
In the FACT trial, FOSAMAX Once-Weekly increased BMD more than Actonel Once-a-WeekFOSAMAX showed greater increases in BMD at all pre-specified meditate endpoints compared to Actonel. Study results showed that FOSAMAX increased BMD 62 percent more than Actonel at the hip trochanter, a specific region of the hip, at 12 months (3.4 percent increase for FOSAMAX vs. 2.1 percent for Actonel; p